Does the media favor BTSG or GRAL?

In the previous week, GRAIL had 2 more articles in the media than BrightSpring Health Services. MarketBeat recorded 9 mentions for GRAIL and 7 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.18 beat GRAIL's score of 0.31 indicating that BrightSpring Health Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BrightSpring Health Services 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has better earnings and valuation, CELC or GRAL?

Celcuity has higher earnings, but lower revenue than GRAIL. Celcuity is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$3.90 N/A GRAIL $147.17M 20.90 -$408.35M -$10.37 N/A

Is CELC or GRAL more profitable?

Celcuity has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. GRAIL's return on equity of -16.42% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -244.61% -50.22% GRAIL -253.22% -16.42% -14.34%

Does the media prefer CELC or GRAL?

In the previous week, GRAIL had 5 more articles in the media than Celcuity. MarketBeat recorded 9 mentions for GRAIL and 4 mentions for Celcuity. Celcuity's average media sentiment score of 0.47 beat GRAIL's score of 0.31 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, GRAL or PACS?

PACS Group has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 20.90 -$408.35M -$10.37 N/A PACS Group $5.29B 1.10 $191.54M $1.56 23.48

Is GRAL or PACS more profitable?

PACS Group has a net margin of 4.49% compared to GRAIL's net margin of -253.22%. PACS Group's return on equity of 26.47% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% PACS Group 4.49% 26.47% 4.36%

Does the media refer more to GRAL or PACS?

In the previous week, GRAIL had 7 more articles in the media than PACS Group. MarketBeat recorded 9 mentions for GRAIL and 2 mentions for PACS Group. GRAIL's average media sentiment score of 0.31 beat PACS Group's score of 0.00 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral PACS Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, GRAL or HIMS?

Hims & Hers Health has higher revenue and earnings than GRAIL. Hims & Hers Health is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 20.90 -$408.35M -$10.37 N/A Hims & Hers Health $2.35B 2.58 $128.37M -$0.09 N/A

Is GRAL or HIMS more profitable?

Hims & Hers Health has a net margin of -0.56% compared to GRAIL's net margin of -253.22%. Hims & Hers Health's return on equity of 6.10% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% Hims & Hers Health -0.56% 6.10% 1.52%

Does the media favor GRAL or HIMS?

In the previous week, Hims & Hers Health had 11 more articles in the media than GRAIL. MarketBeat recorded 20 mentions for Hims & Hers Health and 9 mentions for GRAIL. Hims & Hers Health's average media sentiment score of 0.57 beat GRAIL's score of 0.31 indicating that Hims & Hers Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Hims & Hers Health 9 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Which has better valuation and earnings, GRAL or SHC?

Sotera Health has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 20.90 -$408.35M -$10.37 N/A Sotera Health $1.16B 3.83 $77.94M $0.41 38.15

Is GRAL or SHC more profitable?

Sotera Health has a net margin of 9.91% compared to GRAIL's net margin of -253.22%. Sotera Health's return on equity of 39.73% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% Sotera Health 9.91% 39.73% 7.05%

Does the media favor GRAL or SHC?

In the previous week, GRAIL had 6 more articles in the media than Sotera Health. MarketBeat recorded 9 mentions for GRAIL and 3 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.10 beat GRAIL's score of 0.31 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Sotera Health 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GRAIL (GRAL) Competitors

$71.68 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$72.74 +1.06 (+1.48%)

As of 05/29/2026 07:55 PM Eastern

Compare

GRAL vs. BTSG, CELC, PACS, HIMS, and SHC

Should you buy GRAIL stock or one of its competitors? MarketBeat compares GRAIL with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GRAIL include BrightSpring Health Services (BTSG), Celcuity (CELC), PACS Group (PACS), Hims & Hers Health (HIMS), and Sotera Health (SHC). These companies are all part of the "healthcare" industry.

How does GRAIL compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and GRAIL (NASDAQ:GRAL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

BrightSpring Health Services presently has a consensus target price of $57.00, suggesting a potential downside of 7.59%. GRAIL has a consensus target price of $67.88, suggesting a potential downside of 5.31%. Given GRAIL's higher probable upside, analysts plainly believe GRAIL is more favorable than BrightSpring Health Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.12
GRAIL	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, GRAIL had 2 more articles in the media than BrightSpring Health Services. MarketBeat recorded 9 mentions for GRAIL and 7 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.18 beat GRAIL's score of 0.31 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrightSpring Health Services	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

BrightSpring Health Services has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.15, suggesting that its stock price is 215% more volatile than the broader market.

BrightSpring Health Services has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91B	0.93	$190.67M	$1.41	43.74
GRAIL	$147.17M	20.90	-$408.35M	-$10.37	N/A

BrightSpring Health Services has a net margin of 2.27% compared to GRAIL's net margin of -253.22%. BrightSpring Health Services' return on equity of 14.63% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.27%	14.63%	4.41%
GRAIL	-253.22%	-16.42%	-14.34%

Summary

BrightSpring Health Services beats GRAIL on 11 of the 15 factors compared between the two stocks.

How does GRAIL compare to Celcuity?

Celcuity (NASDAQ:CELC) and GRAIL (NASDAQ:GRAL) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Celcuity has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.15, meaning that its share price is 215% more volatile than the broader market.

Celcuity has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. GRAIL's return on equity of -16.42% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-244.61%	-50.22%
GRAIL	-253.22%	-16.42%	-14.34%

63.3% of Celcuity shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Celcuity has higher earnings, but lower revenue than GRAIL. Celcuity is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A
GRAIL	$147.17M	20.90	-$408.35M	-$10.37	N/A

In the previous week, GRAIL had 5 more articles in the media than Celcuity. MarketBeat recorded 9 mentions for GRAIL and 4 mentions for Celcuity. Celcuity's average media sentiment score of 0.47 beat GRAIL's score of 0.31 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Celcuity currently has a consensus price target of $150.27, suggesting a potential upside of 13.09%. GRAIL has a consensus price target of $67.88, suggesting a potential downside of 5.31%. Given Celcuity's stronger consensus rating and higher possible upside, equities analysts plainly believe Celcuity is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
GRAIL	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Celcuity beats GRAIL on 9 of the 15 factors compared between the two stocks.

How does GRAIL compare to PACS Group?

GRAIL (NASDAQ:GRAL) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

PACS Group has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	20.90	-$408.35M	-$10.37	N/A
PACS Group	$5.29B	1.10	$191.54M	$1.56	23.48

GRAIL presently has a consensus target price of $67.88, suggesting a potential downside of 5.31%. PACS Group has a consensus target price of $48.00, suggesting a potential upside of 31.07%. Given PACS Group's stronger consensus rating and higher possible upside, analysts clearly believe PACS Group is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, GRAIL had 7 more articles in the media than PACS Group. MarketBeat recorded 9 mentions for GRAIL and 2 mentions for PACS Group. GRAIL's average media sentiment score of 0.31 beat PACS Group's score of 0.00 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
PACS Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PACS Group has a net margin of 4.49% compared to GRAIL's net margin of -253.22%. PACS Group's return on equity of 26.47% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
PACS Group	4.49%	26.47%	4.36%

Summary

PACS Group beats GRAIL on 10 of the 13 factors compared between the two stocks.

How does GRAIL compare to Hims & Hers Health?

GRAIL (NASDAQ:GRAL) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Hims & Hers Health has a net margin of -0.56% compared to GRAIL's net margin of -253.22%. Hims & Hers Health's return on equity of 6.10% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
Hims & Hers Health	-0.56%	6.10%	1.52%

GRAIL presently has a consensus price target of $67.88, suggesting a potential downside of 5.31%. Hims & Hers Health has a consensus price target of $28.70, suggesting a potential upside of 9.88%. Given Hims & Hers Health's higher probable upside, analysts plainly believe Hims & Hers Health is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12

63.5% of Hims & Hers Health shares are held by institutional investors. 1.8% of GRAIL shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GRAIL has a beta of 3.15, meaning that its stock price is 215% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than GRAIL. Hims & Hers Health is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	20.90	-$408.35M	-$10.37	N/A
Hims & Hers Health	$2.35B	2.58	$128.37M	-$0.09	N/A

In the previous week, Hims & Hers Health had 11 more articles in the media than GRAIL. MarketBeat recorded 20 mentions for Hims & Hers Health and 9 mentions for GRAIL. Hims & Hers Health's average media sentiment score of 0.57 beat GRAIL's score of 0.31 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Hims & Hers Health	9 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Hims & Hers Health beats GRAIL on 11 of the 15 factors compared between the two stocks.

How does GRAIL compare to Sotera Health?

GRAIL (NASDAQ:GRAL) and Sotera Health (NASDAQ:SHC) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

GRAIL presently has a consensus price target of $67.88, indicating a potential downside of 5.31%. Sotera Health has a consensus price target of $20.33, indicating a potential upside of 30.01%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts plainly believe Sotera Health is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Sotera Health has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	20.90	-$408.35M	-$10.37	N/A
Sotera Health	$1.16B	3.83	$77.94M	$0.41	38.15

In the previous week, GRAIL had 6 more articles in the media than Sotera Health. MarketBeat recorded 9 mentions for GRAIL and 3 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.10 beat GRAIL's score of 0.31 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Sotera Health	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of Sotera Health shares are owned by institutional investors. 1.8% of GRAIL shares are owned by insiders. Comparatively, 15.4% of Sotera Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

GRAIL has a beta of 3.15, meaning that its stock price is 215% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Sotera Health has a net margin of 9.91% compared to GRAIL's net margin of -253.22%. Sotera Health's return on equity of 39.73% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
Sotera Health	9.91%	39.73%	7.05%

Summary

Sotera Health beats GRAIL on 13 of the 16 factors compared between the two stocks.

Get GRAIL News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAL vs. The Competition

Export

Metric	GRAIL	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.08B	$3.40B	$6.41B	$12.57B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	-6.91	18.88	21.61	26.27
Price / Sales	20.90	334.85	561.77	114.93
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	1.08	6.93	10.04	6.86
Net Income	-$408.35M	$24.20M	$3.56B	$337.26M
7 Day Performance	6.68%	4.11%	2.82%	3.58%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	90.13%	66.00%	37.62%	39.67%

GRAIL Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAL GRAIL	0.9838 of 5 stars	$71.68 flat	$67.88 -5.3%	+90.1%	$3.08B	$147.17M	N/A	1,360	Gap Up
BTSG BrightSpring Health Services	4.3062 of 5 stars	$58.50 flat	$57.00 -2.6%	+158.7%	$11.34B	$12.91B	41.49	23,500
CELC Celcuity	2.4008 of 5 stars	$138.23 flat	$149.30 +8.0%	+1,145.4%	$6.74B	N/A	N/A	40
PACS PACS Group	3.8602 of 5 stars	$37.78 +0.1%	$48.00 +27.1%	+268.8%	$5.97B	$5.29B	24.22	47,455	Analyst Upgrade
HIMS Hims & Hers Health	3.0979 of 5 stars	$23.71 -0.2%	$28.90 +21.9%	-54.0%	$5.41B	$2.35B	N/A	2,442	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAL) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRAIL (GRAL) Competitors

GRAL vs. BTSG, CELC, PACS, HIMS, and SHC

How does GRAIL compare to BrightSpring Health Services?

Summary

How does GRAIL compare to Celcuity?

Summary

How does GRAIL compare to PACS Group?

Summary

How does GRAIL compare to Hims & Hers Health?

Summary

How does GRAIL compare to Sotera Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRAIL (GRAL) Competitors

GRAL vs. BTSG, CELC, PACS, HIMS, and SHC

How does GRAIL compare to BrightSpring Health Services?

Do analysts rate BTSG or GRAL?

Does the media favor BTSG or GRAL?

Which has more risk & volatility, BTSG or GRAL?

Which has stronger earnings & valuation, BTSG or GRAL?

Is BTSG or GRAL more profitable?

Summary

How does GRAIL compare to Celcuity?

Which has more volatility & risk, CELC or GRAL?

Is CELC or GRAL more profitable?

Do insiders and institutionals have more ownership in CELC or GRAL?

Which has better earnings and valuation, CELC or GRAL?

Does the media prefer CELC or GRAL?

Do analysts prefer CELC or GRAL?

Summary

How does GRAIL compare to PACS Group?

Which has preferable earnings and valuation, GRAL or PACS?

Do analysts recommend GRAL or PACS?

Does the media refer more to GRAL or PACS?

Is GRAL or PACS more profitable?

Summary

How does GRAIL compare to Hims & Hers Health?

Is GRAL or HIMS more profitable?

Do analysts recommend GRAL or HIMS?

Do institutionals and insiders hold more shares of GRAL or HIMS?

Which has more volatility & risk, GRAL or HIMS?

Which has stronger valuation and earnings, GRAL or HIMS?

Does the media favor GRAL or HIMS?

Summary

How does GRAIL compare to Sotera Health?

Do analysts recommend GRAL or SHC?

Which has better valuation and earnings, GRAL or SHC?

Does the media favor GRAL or SHC?

Do institutionals & insiders believe in GRAL or SHC?

Which has more volatility and risk, GRAL or SHC?

Is GRAL or SHC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools